共查询到20条相似文献,搜索用时 156 毫秒
1.
目的了解整合素连接激酶(intergrin-linked kinase ILK)在非小细胞肺癌中的表达情况.与临床病理特征之间的关系及与非小细胞肺癌患预后的关系并探讨其意义。方法采用免疫组织化学SP法和免疫蛋白印迹法检测ILK在101例非小细胞肺癌(60例鳞癌,41例腺癌)中的表达。结果(1)ILK在非小细胞肺癌组织中的表达高于正常组织且在鳞癌组织中ILK的表达随着分化程度的降低而提高;(2)ILK的表达与临床分期,淋巴结转移等临床病理特征之间无联系(3)ILK的不同表达与非小细胞肺癌患的预后无关。结论目前国内外尚未有ILK在肺癌中的研究,我们的研究表明ILK在非小细胞肺癌中的表达与非小细胞肺癌组织的组织类型来源和恶性程度有关,并可能参与了非小细胞肺癌的发生发展过程。 相似文献
2.
目的:探究波形蛋白在非小细胞肺癌(NSCLC)组织中的表达及其与肺癌浸润转移的相关性。方法:收集2012年6月-2014年6月我院手术切除的NSCLC癌组织标本150例及癌旁正常组织(距肿瘤5 cm)79例,提取两组的RNA,采用实时荧光定量聚合酶链反应(RT-PCR)检测波形蛋白m RNA表达水平,免疫组化法检测波形蛋白的蛋白表达,分析波形蛋白表达水平与淋巴结转移、TNM分期的相关性。结果:波形蛋白m RNA在NSCLC癌组织中的表达明显高于癌旁正常组织(P0.05)。NSCLC癌组织中波形蛋白m RNA表达水平的上调与淋巴结转移及TNM分期(P0.05)相关。结论:波形蛋白在NSCLC患者中表达异常升高,与NSCLC的发生和浸润转移密切相关。 相似文献
3.
目的:探讨survivin在非小细胞肺癌组织(non small cell lung cancer,NSCLC)中的表达,及其与bcl2、p63蛋白表达的相关性。方法:应用二步法免疫组织化法,检测survivin、bcl-2、p63蛋白在60例NSCLC组织和20例正常肺组织中的表达。结果:肺癌组织中的survivin蛋白阳性率(56.67%)明显高于正常肺组织15%),有显著性差异;(p〈0.05)Ⅲ期surviving蛋白阳性表达率72.73%(16/22)明显高于Ⅰ+Ⅲ期survivin47.37%(18/38)。有显著差异;(p〈0.05)survivin蛋白表达与患者年龄、病理类型、组织分化程度,淋巴结转移情况无关(P〉0.05)NSCLC组织bc 1-2蛋白表达阳性、阴性组中,survivin蛋白阳性表达率分别为66.67%(18/27)和48.48%(16/33),两者比较,差异有显著性(P〈0.05);p63蛋白表达阳性、阴性组中,survivin蛋白阳性表达率分别为53-33%(16/30)和60%(18/30),两者比较,差异有显著性(P〈0.05)survivin,蛋白与bc1.2蛋白的表达呈正相关。survivin蛋白与p63蛋白的表达呈正相关。结论:survivin在NSCLC组织中表达上调,通过抑制细胞凋亡,在NSCLC的发生和发展中起到重要作用。survivin,bcl-2与p63它们分别在肺癌发生发展过程中不同途径上抑制肺癌细胞的凋亡,对肺癌早期诊断有一定的意义。对3种蛋白进行联合检测,更有利于肺癌的早期诊断和判断肺癌的分化程度、临床分期、淋巴结是否转移及病人的预后。survivin与bcl-2及survivin与p63可能起协同作用、并可能会成为NSCLC基因治疗的新靶点。 相似文献
4.
原癌基因pokemon mRNA及其蛋白在非小细胞肺癌中的表达和意义 总被引:2,自引:0,他引:2
目的探讨原癌基因PokemonmRNA及其编码蛋白在非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中的表达及其与NSCLC发生的关系。方法应用RT-PCR和原位杂交技术检测pokemon mRNA在NSCLC组织和癌旁正常组织中的相对表达量及细胞定位;利用免疫组织化学染色分析NSCLC组织和癌旁正常组织标本中Pokemon蛋白的表达。结果半定量RT-PCR显示,pokemon mRNA在NSCLC组织中高表达(0.916±0.424),在对应的癌旁正常组织中低表达(0.408±0.307),两组之间具有显著的统计学差异(P<0.05);原位杂交结果显示,pokemon转录本在NSCLC细胞胞质中呈阳性表达,而癌旁正常组织不表达或低表达;免疫组织化学染色分析结果显示,NSCLC组织和对应的癌旁正常组织中Pokemon蛋白阳性表达率分别为87.5%(35/40)和15%(6/40),两组之间具有显著的统计学差异(X2=42.076,P<0.005)。Pokemon蛋白主要定位在癌细胞胞质内,少量定位在胞核中,呈颗粒状分布。结论原癌基因poke-mon mRNA及其编码蛋白在N... 相似文献
5.
目的探讨Nucleostemin(NS,核干细胞因子)基因在非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中的表达及临床意义。方法利用RT-PCR法检测13对NSCLC组织和癌旁正常组织中NS mRNA的表达;采用免疫组织化学SP法检测73例NSCLC组织和13例癌旁正常组织中NS蛋白的表达,并分析与NSCLC患者临床病理特征的关系。结果 NSCLC组织中NS mRNA相对表达强度(0.848±0.305)显著高于癌旁正常组织(0.153±0.020)(t=8.712,P0.01)。NS蛋白在NSCLC中的表达率为58.9%(43/73)显著高于癌旁正常组织中的表达率0%(0/13)(χ2=15.315,P0.01)。NS蛋白的表达率与NSCLC的组织类型及分化程度相关,腺癌组织的表达率为76.5%(26/34)明显高于鳞癌组织的表达率43.6%(17/39)(χ2=8.113,P0.01);低分化组织的表达率81.5%(22/27)明显高于高、中分化组织的表达率45.7%(21/46)(χ2=9.023,P0.01),而与患者性别、年龄、肿瘤大小、TNM分期及淋巴结转移无关(P0.05)。结论 NS基因mRNA及蛋白在NSCLC组织中高表达,对肿瘤细胞的恶性增殖起了重要作用,是一个新的有应用价值的肿瘤分子标志物。 相似文献
6.
目的:探讨Survivin在人非小细胞肺癌组织中表达、临床意义及其与VEGF表达的相关性。方法:采用免疫组织化学(Envision二步法)检测Survivin和VEGF在116例肺鳞癌、腺癌组织及15例肺良性病变组织中的表达情况。结果:Survivin、VEGF的阳性率分别为62.1%(72/116)、72.4%(84/116),显著高于肺良性病变组织的0(0/15)、13.3%(2/15);Survivin表达与非小细胞肺癌的低分化(P〈0.05)、淋巴结转移呈正相关(P〈0.05),与患者预后负相关(P〈0.05);VEGF的表达与肺癌组织的分化程度、TNM分期及淋巴结转移均有关(P〈0.05);并且Survivin表达与VEGF表达呈正相关(P〈0.05)。结论:Survivin有望成为肺癌诊断和基因治疗的新靶点。 相似文献
7.
目的:探讨Survivin在人非小细胞肺癌组织中表达、临床意义及其与VEGF表达的相关性。方法:采用免疫组织化学(Envision二步法)检测Survivin和VEGF在116例肺鳞癌、腺癌组织及15例肺良性病变组织中的表达情况。结果:Survivin、VEGF的阳性率分别为62.1%(72/116)、72.4%(84/116),显著高于肺良性病变组织的0(0/15)、13.3%(2/15);Survivin表达与非小细胞肺癌的低分化(P<0.05)、淋巴结转移呈正相关(P<0.05),与患者预后负相关(P<0.05);VEGF的表达与肺癌组织的分化程度、TNM分期及淋巴结转移均有关(P<0.05);并且Survivin表达与VEGF表达呈正相关(P<0.05)。结论:Survivin有望成为肺癌诊断和基因治疗的新靶点。 相似文献
8.
目的:测定NSCLC组织中kiss-1基因表达、MVD分布,探讨其临床意义及其相关性。方法:应用免疫组化SP法检测56例NSCLC组织中Kiss-1表达及MVD分布情况,分析其与NSCLC的临床病理参数的关系及其相关性。结果:kiss-1在NSCLC表达低于对照组(P〈0.05),MVD在NSCLC分布明显高于对照组(P〈0.05)。Kiss-1与NSCLC的临床分期、淋巴结转移、肿瘤大小有关(P〈0.05)。MVD与NSCLC分化程度、临床分期及淋巴结转移、肿瘤大小有关(P〈0.05).Kiss-1阳性组MVD分布明显低于Kiss-1阴性表达组,二者呈负相关(P〈0.05,r=-0.363)。结论:Kiss-1及MVD在非小细胞肺癌发生、发展中发挥重要作用,二者存在相关性,联合检测可帮助预测NSCLC的侵袭、转移,判断预后。 相似文献
9.
目的:测定NSCLC组织中kiss-1基因表达、MVD分布,探讨其临床意义及其相关性.方法:应用免疫组化SP法检测56例NSCLC组织中Kiss-1表达及MVD分布情况,分析其与NSCLC的临床病理参数的关系及其相关性.结果:Kiss-1在NSCLC表达低于对照组(P<0.05),MVD在NSCLC分布明显高于对照组(P<0.05).Kiss-1与NSCLC的临床分期、淋巴结转移、肿瘤大小有关(P<0.05).MVD与NSCLC分化程度、临床分期及淋巴结转移、肿瘤大小有关(P<0.05).Kiss-1阳性组MVD分布明显低于Kiss-1阴性表达组,二者呈负相关(P<0.05,r=-0.363).结论:Kiss-1及MVD在非小细胞肺癌发生、发展中发挥重要作用,二者存在相关性,联合检测可帮助预测NSCLC的侵袭、转移,判断预后. 相似文献
10.
目的:探讨Med1/TRAP220和uPAR在非小细胞肺癌中表达的临床病理意义.方法:用免疫组织化学技术检测120例非小细胞肺癌组织中Med1/TRAP220和uPAR的表达,并分析其与患者临床病理指标的关系及其和预后的关系.结果:免疫组化结果显示在120例非小细胞肺癌中Med1/TRAP220的阳性表达率为53.3%,uPAR的阳性表达率为70%,癌旁正常肺组织uPAR阳性表达率为12.5%(15/120),Med1/TRAP220的阳性表达率为80%(96/120).uPAR在肺癌中的阳性表达率显著高于癌旁正常肺组织(P<0.01),Med1/TRAP220在癌旁正常肺组织中的阳性表达率显著高于肺癌组织(P<0.01).Med1/TRAP220和uPAR在肺癌中的表达与性别,年龄,肿瘤大小无关(P>0.05).有淋巴结转移组uPAR的阳性表达率显著高于无淋巴结转移组(P<0.05),而无淋巴结转移组Med1/TRAP220的阳性表达率显著高于有淋巴结转移组(P<0.05).uPAR的阳性表达率与非小细胞肺癌的临床分期无显著相关(P>0.05),而Ⅰ-Ⅱ期非小细胞肺癌组Med1/TRAP220的阳性表达率显著高于Ⅲ-Ⅳ期组(P<0.05).uPAR在肺鳞癌和腺癌中的表达率有显著差异(P<0.05),而Med1/TRAP220在肺鳞癌和腺癌中的表达率无显著差异(P>0.05).uPAR阳性组生存率显著低于uPAR阴性组(P<0.05),而Med1/TRAP220阳性组生存率显著高于Med1/TRAP220阴性组(P<0.05).Cox比例危险度模型显示uPAR阳性表达反映不良预后的危险性最大,风险度exp(β)为2.012(P<0.01),其次为肿瘤的TNM分期,风险度exp(β)为1.521,而Med1/TRAP220为预后有利因素,风险度exp(β)为0.386(P<0.01).结论:Med1/TRAP220和uPAR联合应用在非小细胞肺癌预后预测中有重要意义. 相似文献
11.
Lung tumor cell DNA copy number alteration (CNA) was expected to display specific patterns such as a large-scale amplification
or deletion of chromosomal arms, as previously published data have reported. Peripheral blood mononuclear cell (PBMC) CNA
however, was expected to show normal variations in cancer patients as well as healthy individuals, and has thus been used
as normal control DNA samples in various published studies. We performed array CGH to measure and compare genetic changes
in terms of the CNA of PBMC samples as well as DNA isolated from tumor tissue samples, obtained from 24 non-small cell lung
cancer patients. Contradictory to expectations, our studies showed that the PBMC CNA also showed chromosomal variant regions.
The list included well-known tumor-associated NTRK1, FGF8, TP53, and TGFβ1 genes and potentially novel oncogenes such as THPO (3q27.1), JMJD1B, and EGR1 (5q31.2), which was investigated in this study. The results of this study highlighted the connection between PBMC and tumor
cell genomic DNA in lung cancer patients. However, the application of these studies to cancer prognosis may pose a challenge
due to the large amount of information contained in genetic predisposition and family history that has to be processed for
useful downstream clinical applications. 相似文献
12.
目的探讨p16和Ki67在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达,研究它们对NSCLC患者预后的影响及其与临床及病理因素之间的关系。方法收集NSCLC术后标本160例及正常肺组织20例(对照组),应用免疫组化法检测NSCLC组织和正常肺组织中p16和Ki67的表达。结果在NSCLC组织和正常肺组织中,p16和Ki67的阳性表达率分别为23.8%、82.5%和90%、5%,差异有统计学意义(P〈0.05)。多因素分析:PTNM分期、淋巴结转移、p16及Ki67的表达是影响NSCLC根治术后患者预后的独立因素(P〈0.05);p16阳性组与阴性组5年生存率分别为55.3%和18.0%,差异有统计学意义(P〈0.05);Ki67阳性组与阴性组5年生存率分别为23.5%和42.9%,差异有统计学意义(P〈0.05),p16和Ki67表达呈负相关(P〈0.05)。结论 p16和Ki67参与了NSCLC的发生发展,p16和Ki67的表达水平与NSCLC的发展及预后有一定的关系。 相似文献
13.
Aysun Ozkan 《Biologia》2007,62(2):232-237
The aim of this study was to evaluate that: (i) epirubicin-HCl (EPI) and lymphokine-activated killer (LAK) cells cytotoxicity
may be mediated by free radical generation; and (ii) resistant H1299 cells may be more sensitive to combined treatment of
LAK cells plus EPI than the LAK or EPI treatment alone. Viability of H1299 cells treated with EPI, LAK and LAK plus EPI was
measured using the MTT test. Amount of glutathione (GSH), protein content and enzymatic activity were measured by spectrophotometer.
Glutathione S-transferase (GST)-pi expression in the cells was determined by western blot analysis. LAK plus EPI combined
treatment increased susceptibility of H1299 WT and H1299 EPI(R) (300-fold EPI resistant) cells to LAK cell cytotoxicity. The
resistance of H1299 EPI(R) cells to EPI appears to be associated with a developed tolerance to free radicals, most likely
because of a 2-fold increase in NADPH-dependent-cytochrome-P450 reductase (NADPH-CYP reductase) activity, 11-fold GST activity
and 11-and 7-fold augmented selenium dependent and independent glutathione peroxidase (GSH-Px) activity, respectively. Amount
of GST-pi in H1299 EPI(R) cells is statistically different from negative control and H1299 WT (p < 0.01). It is proposed that production of reactive oxygen species and hydrogen peroxide by the treatment of EPI and LAK
cells can cause cytotoxicity of H1299 WT and H1299 EPI(R) cells. Superoxide dismutase, catalase, GSH-Px, GST, NADPH-CYP reductase
and GSH must be considered as part of the intracellular antioxidant defense mechanism of H1299 WT and H1299 EPI(R) cells against
reactive oxygen species. Combined treatment of EPI plus LAK cells caused the increasing cytotoxicity on the H1299 EPI(R) cells. 相似文献
14.
Lung cancer is the most common cause of cancer mortality in male and female patients in the US. The etiology of non-small cell lung cancer (NSCLC) is not fully defined, but new data suggest that estrogens and growth factors promote tumor progression. In this work, we confirm that estrogen receptors (ER), both ERalpha and ERbeta, occur in significant proportions of archival NSCLC specimens from the clinic, with receptor expression in tumor cell nuclei and in extranuclear sites. Further, ERalpha in tumor nuclei was present in activated forms as assessed by detection of ER phosphorylation at serines-118 and -167, residues commonly modulated by growth factor receptor as well as steroid signaling. In experiments using small interfering RNA (siRNA) constructs, we find that suppressing expression of either ERalpha or ERbeta elicits a significant reduction in NSCLC cell proliferation in vitro. Estrogen signaling in NSCLC cells may also include steroid receptor coactivators (SRC), as SRC-3 and MNAR/PELP1 are both expressed in several lung cell lines, and both EGF and estradiol elicit serine phosphorylation of SRC-3 in vitro. EGFR and ER also cooperate in promoting early activation of p42/p44 MAP kinase in NSCLC cells. To assess new strategies to block NSCLC growth, we used Faslodex alone and with erlotinib, an EGFR kinase inhibitor. The drug tandem elicited enhanced blockade of the growth of NSCLC xenografts in vivo, and antitumor activity exceeded that of either agent given alone. The potential for use of antiestrogens alone and with growth factor receptor antagonists is now being pursued further in clinical trials. 相似文献
15.
16.
目的检测Hey1与Notch1在非小细胞肺癌组织中的表达,探讨Hey1在非小细胞肺癌中的表达与Notch1的表达、各临床病理特征之间的关系。方法制作组织芯片,采用免疫组织化学染色检测Notch1和Hey1在246例非小细胞肺癌组织及相应117例癌旁正常肺组织中的表达,应用SPSS 21.0进行统计分析。结果 Notch1在肺鳞癌、肺腺癌和癌旁正常肺组织的阳性率分别为78.8%,28.9%和30.8%,Hey1在肺鳞癌、肺腺癌和癌旁正常肺组织中的阳性率分别为79.7%,23.4%和33.3%;肺鳞癌患者Notch1阳性表达与TNM分期和淋巴结转移情况呈正相关;肺鳞癌患者Hey1阳性表达与TNM分期呈正相关,与肿瘤分化程度呈负相关;Spearman相关分析显示,肺鳞癌和肺腺癌组织中Notch1表达与Hey1表达具有显著的正相关关系。结论 Hey1和Notch1与肺鳞癌的恶性程度密切相关,可能是肺鳞癌发生、发展的重要参与因子。 相似文献
17.
BackgroundPD-L1 expression on tumor cells (TCs) or immune cells (ICs) may be used as a prognostic marker for survival in patients with NSCLC. We characterized PD-L1 expression on TCs or ICs in a patient cohort with NSCLC to determine associations between PD-L1 expression and overall survival (OS), according to EGFR and KRAS mutation status.MethodsDanish patients aged >18 years diagnosed with NSCLC before 2014 on first- (N = 491), second- (N = 368), or third-line (N = 498) therapy were included. Data were extracted from population-based medical registries. Tumor samples from pathology archives were tested for biomarkers. High PD-L1 expression was defined as expression on ≥25 % of TCs or ICs based on first diagnostic biopsy or surgical resection. KRAS and EGFR mutation status were tested using PCR-based assays. Cox regression analysis was used to compute adjusted HRs and associated 95 % CIs.ResultsPD-L1 TC and IC ≥ 25 % were observed in 24.3 %–31.0 % and 11.7–14.7 % of patients, respectively. EGFR and KRAS mutations were detected in 4.7 %–8.8 % and 26.5 %–30.7 % of patients, respectively. PD-L1 TC ≥ 25 % was not associated with survival advantage in first- (HR = 0.96, 95 % CI: 0.75–1.22), second- (1.08, 0.81–1.42), or third-line (0.94, 0.74–1.20) therapy. PD-L1 IC ≥ 25 % was associated with survival advantage in second-line (HR = 0.56, 95 % CI: 0.36–0.86) and third-line (0.69, 0.49–0.97) but not first-line (1.00, 0.70–1.41) therapy.ConclusionNo association was observed between PD-L1 TC ≥ 25 % and OS in any therapy line. PD-L1 IC ≥ 25 % may confer survival benefit among some patients who reach second-line therapy. 相似文献
18.
Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer
Background
In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC.Methods
In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs.Results
ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups.Conclusions
In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results. 相似文献19.
Ning Li Xiaobing Li Suyun Li Suzhen Zhou Qingwei Zhou 《Biochemical and biophysical research communications》2013
SOX1 was aberrant methylated in hepatocellular cancer and non-small cell lung cancer (NSCLC). Long-term cisplatin exposure promotes methylation of SOX1 in ovarian cancer cell, suggesting that SOX1 may be involved in cisplatin resistance. Our aim was to test the hypothesis that cisplatin resistance is associated with alteration of SOX1 expression in NSCLC. Expression of levels of SOX1 was examined using RT-PCR in cisplatin resistance cells and parental cells. The level of SOX1 mRNA in cisplatin resistance cells was markedly reduced when compared to parental cells. Promoter methylation of SOX1 was induced in cisplatin resistance cells. We also found that SOX1 silencing enhanced the cisplatin-mediated autophagy in NSCLC. This study shows that inactivation of SOX1 by promoter hypermethylation, at least in part, is responsible for cisplatin resistance in human NSCLC. 相似文献
20.
Maoshu Zhu Hui Zhang Fuhua Lu Zhaowei Wang Yulong Wu Huoshu Chen Xin Fan Zhijiang Yin Fulong Liang 《Bioscience reports》2021,41(10)
Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer. Ubiquitination is closely related to the development of lung cancer. However, the biological importance of newly discovered ubiquitin-specific peptidase (USP) 52 (USP52) in NSCLC remained unclear. Here, our findings identify USP52 as a novel tumor suppressor of NSCLC, the low expression of USP52 predicts a poor prognosis for NSCLC patients. The present study demonstrates that USP52 inhibits cancer cell proliferation through down-regulation of cyclin D1 (CCND1) as well as AKT/mTOR signaling pathway inhibition. Meanwhile, USP25 also suppresses NSCLC progression via enhancing phosphatase and tensin homolog (PTEN) stability in cancer cells, which further indicates the significance/importance of USP52 in NSCLC suppression. 相似文献